Enveric Biosciences, Inc. (ENVB)

Enveric Biosciences Secures New U.S. Patent Allowance for Next-Generation, Non-Hallucinogenic Mescaline Derivatives in EVM401 Series

Enveric Biosciences to Present at H.C. Wainwright 28th Annual Global Investment Conference

Enveric Biosciences Reports Financial Results and Provides Corporate Update for Second Quarter 2026

Enveric Biosciences Says New Preclinical Data Confirms Non-Hallucinogenic Profile For Lead Psychiatric Candidate

Enveric Biosciences Reports New Preclinical Data Supporting the Non-Hallucinogenic Profile of Lead Candidate EB-003

Enveric Biosciences Welcomes Final FDA Guidance for Psychedelic Drug Development